The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy

Dalin Li¹, Alexander Xu², Emebet Mengesha¹, Rebecca Elyanow³, Rachel M Gittelman³, Heidi Chapman³, John C Prostko⁴, Edwin C Frias⁴, James L Stewart⁴, Valeriya Pozdnyakova¹, Philip Debbas¹, Angela Mujukian¹, Arash A Horizon⁵, Noah Merin², Sandy Joung⁶, Gregory J Botwin¹, Kimia Sobhani⁷, Jane C Figueiredo², Susan Cheng⁶, Ian M Kaplan², Dermot P B McGovern¹, Akil Merchant², Gil Y Melmed¹, Jonathan Braun^{1

7}

Affiliations

¹ F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
² Cedars Sinai Cancer and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
³ Adaptive Biotechnologies, Seattle, WA, USA.
⁴ Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL.
⁵ Center for Rheumatology Medical Group, Los Angeles, CA, USA.
⁶ Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
⁷ Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

PMID: 35397000
PMCID: PMC9047232
DOI: 10.1093/ibd/izac071

The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy

Dalin Li et al. Inflamm Bowel Dis. 2022.

. 2022 Jul 1;28(7):1130-1133.

doi: 10.1093/ibd/izac071.

Authors

Affiliations

¹ F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
² Cedars Sinai Cancer and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
³ Adaptive Biotechnologies, Seattle, WA, USA.
⁴ Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL.
⁵ Center for Rheumatology Medical Group, Los Angeles, CA, USA.
⁶ Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
⁷ Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

PMID: 35397000
PMCID: PMC9047232
DOI: 10.1093/ibd/izac071

No abstract available

Keywords: IBD biologic therapy; SARS-CoV-2; T-cell response; TCR clonal; antibody response; inflammatory bowel disease; vaccination.

Plain language summary

T-cell and antibody responses to severe acute respiratory syndrome coronavirus 2 vaccination in inflammatory bowel disease patients are poorly correlated. T-cell responses are preserved by most biologic therapies, but augmented by anti-tumor necrosis factor (anti-TNF) treatment. While anti-TNF therapy blunts the antibody response, cellular immunity after vaccination is robust.

PubMed Disclaimer

Figures

**Figure 1.**
T-cell clonal response to SARS-CoV-2 immunization. (A) Box plots show means, quartiles, and data ranges. Relative to dose 1, P values (mixed-effect model analysis with adjustment for age and sex) for dose 2, at 2 weeks after the second vaccination, and at 8 weeks after the second vaccination were 9.87E-11, 2.42E-25, and 5.30E-14, respectively (n = 88 at dose 1, 148 at dose 2, 136 at 2 weeks, and 163 at 8 weeks). (B) Age. Numbers of subjects by age group are tabulated in Table 1. (C) Immunologic treatment and response at week 2. No Imm (n = 19), anti-integrin (n = 14), anti-IL23 (n = 36), anti-TNF mono (n = 36), anti-TNF cmb (n = 11), steroids/small mol (n = 16). Boxes are mean values, bars are data ranges, and P values were calculated by ANOVA after adjustment for age, sex, vaccine type, and COVID-19 history. (D) T-cell response and anti-spike IgG levels at week 2 (Spearman’s correlation; N = 148). (E) T-cell response at week 2 (blue, lowest quartile; red, remaining quartiles; N = 148). (F) Anti-spike IgG levels at week 2 by subject distribution (blue, lowest T-cell response quartile; red, remaining T-cell response quartiles; N = 148). Abbreviations: anti-TNF cmb, combined therapy with anti-tumor necrosis factor and a thiopurine or methotrexate; ANOVA, analysis of variance; anti-TNF mono, monotherapy with anti-tumor necrosis factor; Ig, immunoglobin; IL, interleukin; JAK, Janus kinase; no Imm, no treatment, 5-aminosalicylates, or rectal steroids; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; steroids/small mol, treatment with systemic corticosteroids or monotherapy with thiopurines, methotrexate, or Janus kinase inhibitors; TNF, tumor necrosis factor.

See this image and copyright information in PMC

Update of

The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders.
Li D, Xu A, Mengesha E, Elyanow R, Gittelman RM, Chapman H, Prostko JC, Frias EC, Stewart JL, Pozdnyakova V, Debbas P, Mujukian A, Horizon AA, Merin N, Joung S, Botwin GJ, Sobhani K, Figueiredo JC, Cheng S, Kaplan IM, McGovern DPB, Merchant A, Melmed GY, Braun J. Li D, et al. medRxiv [Preprint]. 2021 Dec 8:2021.12.08.21267444. doi: 10.1101/2021.12.08.21267444. medRxiv. 2021. Update in: Inflamm Bowel Dis. 2022 Jul 1;28(7):1130-1133. doi: 10.1093/ibd/izac071. PMID: 34909785 Updated. Preprint.

References

1. Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, et al. Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti-TNFα. Gastroenterology. 2022;162(2):454–467. - PMC - PubMed
1. Kennedy NA, Lin S, Goodhand JR, et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021;70(10):1884–1893. - PubMed
1. Melmed GY, Botwin GJ, Sobhani K, et al. Antibody responses after SARS-CoV-2 mRNA vaccination in adults with inflammatory bowel disease. Ann Intern Med. 2021;174(12):1768–1770. - PMC - PubMed
1. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590(7847):630–634. - PMC - PubMed
1. Botwin GJ, Li D, Figueiredo J, et al. Adverse events after SARS-CoV-2 mRNA vaccination among patients with inflammatory bowel disease. Am J Gastroenterol. doi: 10.1101/2021.03.30.21254607, 31 March 2021, preprint: not peer reviewed. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy

Affiliations

The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy

Authors

Affiliations

Plain language summary

Figures

Update of

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous